| Stage | BSX | % of rev | MDT | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $5.1B | 100.00% | $9.8B | 100.00% | MDT ×1.90 |
| Gross profit | $3.4B | 66.72% | $6.3B | 64.99% | BSX +1.7pp |
| Operating income | $828M | 16.12% | $1.8B | 18.08% | MDT +2.0pp |
| Pre-tax income | $733M | 14.27% | $1.8B | 18.13% | MDT +3.9pp |
| Net income | $580M | 11.29% | $1.5B | 15.16% | MDT +3.9pp |
| Stage | BSX | MDT | Gap · A − B |
|---|---|---|---|
| Revenue | $5.1B100.00% | $9.8B100.00% | MDT ×1.90 |
| Gross profit | 66.72%$3.4B | 64.99%$6.3B | BSX +1.7pp |
| Operating income | 16.12%$828M | 18.08%$1.8B | MDT +2.0pp |
| Pre-tax income | 14.27%$733M | 18.13%$1.8B | MDT +3.9pp |
| Net income |
| 11.29%$580M |
| 15.16%$1.5B |
| MDT +3.9pp |
None
BSX · ITGR 10-KFeb 23 '26
“During 2025, three of our customers, Abbott Laboratories, Boston Scientific and Medtronic were each in excess of 10% of total sales and collectively accounted for 49% of our total sales.”
MDT · ITGR 10-KFeb 23 '26
“During 2025, three of our customers, Abbott Laboratories, Boston Scientific and Medtronic were each in excess of 10% of total sales and collectively accounted for 49% of our total sales.”
BSX · ELUT 10-KMar 13 '26
“On September 8, 2025, Elutia executed an Asset Purchase Agreement (the "APA") with Boston Scientific Corporation ("BSC"), a Delaware corporation, and Cardiac Pacemakers Inc. ("CPI"), a Minnesota corporation (collectively with BSC, the " CIED Buyers").”
MDT · ELUT 10-KMar 13 '26
“In particular, the complaint alleges that Medtronic did not honor its contractual obligations to defend and indemnify the Company for over 100 lawsuits against the Company alleging claims arising from the use of FiberCel products distributed by Medtronic and that Medtronic concealed and misrepresented an insurance policy potentially applicable to those FiberCel-related lawsuits.”